ProNAi Therapeutics Inc. (NASDAQ:DNAI)’s share price was up 6% on Monday . The company traded as high as $2.15 and last traded at $2.13, with a volume of 1,182,737 shares. The stock had previously closed at $2.01.

A number of equities analysts recently weighed in on DNAI shares. Zacks Investment Research cut ProNAi Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 4th. Wedbush reissued an “outperform” rating and issued a $36.00 price target on shares of ProNAi Therapeutics in a research note on Friday, May 27th. Jefferies Group reissued a “buy” rating on shares of ProNAi Therapeutics in a research note on Sunday, May 29th. Finally, SunTrust Banks Inc. cut ProNAi Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $25.00 to $4.00 in a research note on Monday, June 6th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. ProNAi Therapeutics currently has an average rating of “Hold” and a consensus target price of $17.35.

The firm’s market capitalization is $62.16 million. The company has a 50 day moving average price of $2.51 and a 200 day moving average price of $5.96.

ProNAi Therapeutics (NASDAQ:DNAI) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.07. Equities research analysts predict that ProNAi Therapeutics Inc. will post ($1.33) earnings per share for the current fiscal year.

An institutional investor recently bought a new position in ProNAi Therapeutics stock. Jennison Associates purchased a new stake in shares of ProNAi Therapeutics Inc. (NASDAQ:DNAI) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 150,381 shares of the company’s stock, valued at approximately $3,086,000. Jennison Associates owned about 0.50% of ProNAi Therapeutics as of its most recent SEC filing.

ProNAi Therapeutics, Inc is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.